HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Treatment of rheumatoid arthritis by interleukin-1 receptor antagonist].

AbstractPURPOSE:
Interleukin -1 receptor antagonist ( IL-1Ra ) is a new option among biotherapies against rheumatoid arthritis ( RA ).
THE AIM:
of this review is to recall the rationale of use of IL-1Ra and to analyse the results available in the current literature.
CURRENT KNOWLEDGE AND KEY POINTS:
Pathophysiological data of RA give a specific position for IL-1 as a potential target for immunotherapy in this disease, confirmed in animal models. Phase II and III studies with IL-1Ra (Anakinra) demonstrated clinical efficacy versus placebo (42% responders in ACR 20 in Anakinra + methotrexate, and 23% in the placebo + methotrexate group at 24 weeks) and a structural effect (slowing of radiological progression at six months). Anakinra has obtained an European license and is indicated in RA not controlled by methotrexate, in daily subcutaneous administration (100 mg/day), in combination with methotrexate. Tolerance is fair; the most frequent side effect is represented by injection site reactions.
FUTURE PROSPECTS AND PROJECTS:
This ambulatory biotherapy offers new perspectives in combination with other slow acting drugs as well as biologic agents such as anti-TNF, currently under evaluation.
AuthorsD Wendling, C Jorgensen
JournalLa Revue de medecine interne (Rev Med Interne) Vol. 23 Issue 12 Pg. 1006-11 (Dec 2002) ISSN: 0248-8663 [Print] France
Vernacular TitleTraitement de la polyarthrite rhumatoïde par l'antagoniste du récepteur de l'interleukine 1.
PMID12504237 (Publication Type: English Abstract, Journal Article, Review)
Chemical References
  • IL1RN protein, human
  • Interleukin 1 Receptor Antagonist Protein
  • Receptors, Interleukin-1
  • Sialoglycoproteins
Topics
  • Animals
  • Arthritis, Rheumatoid (drug therapy)
  • Clinical Trials as Topic
  • Disease Models, Animal
  • Drug Therapy, Combination
  • Humans
  • Interleukin 1 Receptor Antagonist Protein
  • Receptors, Interleukin-1 (antagonists & inhibitors)
  • Sialoglycoproteins (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: